{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T23:00:53Z","timestamp":1790118053849,"version":"4.0.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"39","license":[{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2026,10,14]]},"DOI":"10.1038\/s41388-026-03931-5","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T14:15:35Z","timestamp":1786025735000},"page":"4132-4148","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["AKAP13 regulates GLI1\/ULK1 axis and drive tumor resistance to next-generation HER2-targeted therapies"],"prefix":"10.1038","volume":"45","author":[{"given":"Qing","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linfeng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changhao","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yourong","family":"Jian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingxi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yizi","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxin","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2877-8642","authenticated-orcid":false,"given":"Yuanyuan","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7807-3492","authenticated-orcid":false,"given":"Jian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,6]]},"reference":[{"key":"3931_CR1","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/j.annonc.2022.08.001","volume":"33","author":"JE Augustin","year":"2022","unstructured":"Augustin JE, Soussan P, Bass AJ. Targeting the complexity of ERBB2 biology in gastroesophageal carcinoma. Ann Oncol. 2022;33:1134\u201348.","journal-title":"Ann Oncol"},{"key":"3931_CR2","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41571-023-00849-9","volume":"21","author":"A Marra","year":"2024","unstructured":"Marra A, Chandarlapaty S, Modi S. Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectives. Nat Rev Clin Oncol. 2024;21:185\u2013202.","journal-title":"Nat Rev Clin Oncol"},{"key":"3931_CR3","doi-asserted-by":"publisher","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024. https:\/\/doi.org\/10.3322\/caac.21834.","DOI":"10.3322\/caac.21834"},{"key":"3931_CR4","doi-asserted-by":"publisher","unstructured":"Nolan E, Lindeman GJ, Visvader JE. Deciphering breast cancer: from biology to the clinic. Cell 2023;0. https:\/\/doi.org\/10.1016\/j.cell.2023.01.040.","DOI":"10.1016\/j.cell.2023.01.040"},{"key":"3931_CR5","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1158\/1078-0432.CCR-20-2701","volume":"27","author":"M Shah","year":"2021","unstructured":"Shah M, Wedam S, Cheng J, Fiero MH, Xia H, Li F, et al. FDA approval summary: tucatinib for the treatment of patients with advanced or metastatic HER2-positive breast cancer. Clin Cancer Res. 2021;27:1220\u20136.","journal-title":"Clin Cancer Res"},{"key":"3931_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100063","volume":"6","author":"C Corti","year":"2021","unstructured":"Corti C, Criscitiello C. Tucatinib approval by EMA expands options for HER2-positive locally advanced or metastatic breast cancer. ESMO Open. 2021;6:100063.","journal-title":"ESMO Open"},{"key":"3931_CR7","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/NEJMoa1914510","volume":"382","author":"S Modi","year":"2020","unstructured":"Modi S, Saura C, Yamashita T, Park YH, Kim S-B, Tamura K, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med. 2020;382:610\u201321.","journal-title":"N Engl J Med"},{"key":"3931_CR8","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1158\/1535-7163.MCT-19-0873","volume":"19","author":"A Kulukian","year":"2020","unstructured":"Kulukian A, Lee P, Taylor J, Rosler R, de Vries P, Watson D, et al. Preclinical activity of HER2-selective tyrosine kinase inhibitor tucatinib as a single agent or in combination with trastuzumab or docetaxel in solid tumor models. Mol Cancer Ther. 2020;19:976\u201387.","journal-title":"Mol Cancer Ther"},{"key":"3931_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2024.101126","volume":"77","author":"Y Zou","year":"2024","unstructured":"Zou Y, Yang A, Chen B, Deng X, Xie J, Dai D, et al. crVDAC3 alleviates ferroptosis by impeding HSPB1 ubiquitination and confers trastuzumab deruxtecan resistance in HER2-low breast cancer. Drug Resistance Updates. 2024;77:101126.","journal-title":"Drug Resistance Updates"},{"key":"3931_CR10","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1038\/s41416-020-01257-x","volume":"124","author":"NT Conlon","year":"2021","unstructured":"Conlon NT, Kooijman JJ, van Gerwen SJC, Mulder WR, Zaman GJR, Diala I, et al. Comparative analysis of drug response and gene profiling of HER2-targeted tyrosine kinase inhibitors. Br J Cancer. 2021;124:1249\u201359.","journal-title":"Br J Cancer"},{"key":"3931_CR11","doi-asserted-by":"publisher","first-page":"PD8\u201306","DOI":"10.1158\/1538-7445.SABCS21-PD8-06","volume":"82","author":"J Veeraraghavan","year":"2022","unstructured":"Veeraraghavan J, Bose S, Mistry R, Selenica P, Nanda S, Qin L, et al. Abstract PD8-06: Acquired resistance to tucatinib is associated with EGFR amplification in HER2+ breast cancer (BC) models and can be overcome by a more complete blockade of HER receptor layer. Cancer Res. 2022;82:PD8\u201306.","journal-title":"Cancer Res"},{"key":"3931_CR12","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1038\/nrm1527","volume":"5","author":"W Wong","year":"2004","unstructured":"Wong W, Scott JD. AKAP signalling complexes: focal points in space and time. Nat Rev Mol Cell Biol. 2004;5:959\u201370.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"3931_CR13","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1126\/science.aaj1669","volume":"356","author":"FD Smith","year":"2017","unstructured":"Smith FD, Esseltine JL, Nygren PJ, Veesler D, Byrne DP, Vonderach M, et al. Local protein kinase A action proceeds through intact holoenzymes. Science. 2017;356:1288\u201393.","journal-title":"Science"},{"key":"3931_CR14","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/nrm3966","volume":"16","author":"LK Langeberg","year":"2015","unstructured":"Langeberg LK, Scott JD. Signalling scaffolds and local organization of cellular behaviour. Nat Rev Mol Cell Biol. 2015;16:232\u201344.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"3931_CR15","doi-asserted-by":"publisher","first-page":"20990","DOI":"10.1073\/pnas.0710527105","volume":"104","author":"L Chen","year":"2007","unstructured":"Chen L, Marquardt ML, Tester DJ, Sampson KJ, Ackerman MJ, Kass RS. Mutation of an A-kinase-anchoring protein causes long-QT syndrome. Proc Natl Acad Sci USA 2007;104:20990\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3931_CR16","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.molcel.2012.09.002","volume":"48","author":"DA Canton","year":"2012","unstructured":"Canton DA, Keene CD, Swinney K, Langeberg LK, Nguyen V, Pelletier L, et al. Gravin is a transitory effector of polo-like kinase 1 during cell division. Mol Cell. 2012;48:547\u201359.","journal-title":"Mol Cell"},{"key":"3931_CR17","doi-asserted-by":"publisher","unstructured":"Sa H, Mf N, A U, Jl W, Pj N, G T, et al. Anchored phosphatases modulate glucose homeostasis. EMBO J. 2012;31. https:\/\/doi.org\/10.1038\/emboj.2012.244.","DOI":"10.1038\/emboj.2012.244"},{"key":"3931_CR18","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1158\/1078-0432.CCR-06-2609","volume":"13","author":"M Raponi","year":"2007","unstructured":"Raponi M, Harousseau J-L, Lancet JE, L\u00f6wenberg B, Stone R, Zhang Y, et al. Identification of molecular predictors of response in a study of tipifarnib treatment in relapsed and refractory acute myelogenous leukemia. Clin Cancer Res. 2007;13:2254\u201360.","journal-title":"Clin Cancer Res"},{"key":"3931_CR19","doi-asserted-by":"publisher","first-page":"W739","DOI":"10.1093\/nar\/gkac382","volume":"50","author":"A Ianevski","year":"2022","unstructured":"Ianevski A, Giri AK, Aittokallio T. SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples. Nucleic Acids Res. 2022;50:W739\u201343.","journal-title":"Nucleic Acids Res"},{"key":"3931_CR20","doi-asserted-by":"publisher","first-page":"4101","DOI":"10.1016\/j.csbj.2021.07.014","volume":"19","author":"B Gy\u0151rffy","year":"2021","unstructured":"Gy\u0151rffy B. Survival analysis across the entire transcriptome identifies biomarkers with the highest prognostic power in breast cancer. Comput Struct Biotechnol J. 2021;19:4101\u20139.","journal-title":"Comput Struct Biotechnol J"},{"key":"3931_CR21","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2:401\u20134.","journal-title":"Cancer Discov"},{"key":"3931_CR22","doi-asserted-by":"publisher","first-page":"3861","DOI":"10.1158\/0008-5472.CAN-23-0816","volume":"83","author":"I de Bruijn","year":"2023","unstructured":"de Bruijn I, Kundra R, Mastrogiacomo B, Tran TN, Sikina L, Mazor T, et al. Analysis and visualization of longitudinal genomic and clinical data from the AACR Project GENIE Biopharma Collaborative in cBioPortal. Cancer Res. 2023;83:3861\u20137.","journal-title":"Cancer Res"},{"key":"3931_CR23","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41586-019-1186-3","volume":"569","author":"M Ghandi","year":"2019","unstructured":"Ghandi M, Huang FW, Jan\u00e9-Valbuena J, Kryukov GV, Lo CC, McDonald ER, et al. Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature. 2019;569:503\u20138.","journal-title":"Nature"},{"key":"3931_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-12-35","volume":"12","author":"H Chen","year":"2011","unstructured":"Chen H, Boutros PC. VennDiagram: a package for the generation of highly-customizable Venn and Euler diagrams in R. BMC Bioinforma. 2011;12:35.","journal-title":"BMC Bioinforma"},{"key":"3931_CR25","doi-asserted-by":"publisher","DOI":"10.1002\/imt2.36","volume":"1","author":"W Shen","year":"2022","unstructured":"Shen W, Song Z, Zhong X, Huang M, Shen D, Gao P, et al. Sangerbox: A comprehensive, interaction-friendly clinical bioinformatics analysis platform. iMeta. 2022;1:e36.","journal-title":"iMeta"},{"key":"3931_CR26","doi-asserted-by":"publisher","first-page":"e0294236","DOI":"10.1371\/journal.pone.0294236","volume":"18","author":"D Tang","year":"2023","unstructured":"Tang D, Chen M, Huang X, Zhang G, Zeng L, Zhang G, et al. SRplot: A free online platform for data visualization and graphing. PLoS One. 2023;18:e0294236.","journal-title":"PLoS One"},{"key":"3931_CR27","doi-asserted-by":"crossref","unstructured":"Ji X, Tang J, Zhang J. Effects of salt stress on the morphology, growth and physiological parameters of Juglans microcarpa L. Seedlings. Plants. 2022;11:2381.","DOI":"10.3390\/plants11182381"},{"key":"3931_CR28","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1074\/jbc.C500300200","volume":"281","author":"T Sheng","year":"2006","unstructured":"Sheng T, Chi S, Zhang X, Xie J. Regulation of Gli1 localization by the cAMP\/protein kinase A signaling axis through a site near the nuclear localization signal *. J Biol Chem. 2006;281:9\u201312.","journal-title":"J Biol Chem"},{"key":"3931_CR29","doi-asserted-by":"crossref","unstructured":"Kaesler S, L\u00fcscher B, R\u00fcther U. Transcriptional activity of GLI1 is negatively regulated by protein kinase A. 2000;381:545\u201351.","DOI":"10.1515\/BC.2000.070"},{"key":"3931_CR30","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/j.chembiol.2016.07.015","volume":"23","author":"D Diviani","year":"2016","unstructured":"Diviani D, Raimondi F, Del Vescovo CD, Dreyer E, Reggi E, Osman H, et al. Small-molecule protein-protein interaction inhibitor of oncogenic Rho signaling. Cell Chem Biol. 2016;23:1135\u201346.","journal-title":"Cell Chem Biol"},{"key":"3931_CR31","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1007\/s43032-022-01097-5","volume":"30","author":"KC Cayton Vaught","year":"2023","unstructured":"Cayton Vaught KC, Hazimeh D, Carter AS, Devine K, Maher JY, Maguire M, et al. AKAP13 enhances CREB1 activation by FSH in Granulosa cells. Reprod Sci. 2023;30:1528\u201339.","journal-title":"Reprod Sci"},{"key":"3931_CR32","first-page":"118","volume":"3","author":"JY Maher","year":"2022","unstructured":"Maher JY, Islam MS, Yin O, Brennan J, Gough E, Driggers P, et al. The role of Hippo pathway signaling and A-kinase anchoring protein 13 in primordial follicle activation and inhibition. FS Sci. 2022;3:118\u201329.","journal-title":"FS Sci"},{"key":"3931_CR33","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.fertnstert.2020.12.011","volume":"116","author":"CNC Mitchell","year":"2021","unstructured":"Mitchell CNC, Islam MS, Afrin S, Brennan J, Psoter KJ, Segars JH. Mechanical stiffness augments ligand-dependent progesterone receptor B activation via MEK 1\/2 and Rho\/ROCK\u2013dependent signaling pathways in uterine fibroid cells. Fertil Steril. 2021;116:255\u201365.","journal-title":"Fertil Steril"},{"key":"3931_CR34","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2417586122","volume":"122","author":"Y-F Chen","year":"2025","unstructured":"Chen Y-F, Zhang Q-H, Zhang Z-W, Zhou Y-J, Liu C-C, Shao Z-M, et al. SNX10 deficiency impairs sensitivity to anti-HER2 antibody-drug conjugates via altering HER2 trafficking in HER2-positive breast cancer. Proc Natl Acad Sci USA 2025;122:e2417586122.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3931_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101792","volume":"5","author":"A Gupta","year":"2024","unstructured":"Gupta A, Michelini F, Shao H, Yeh C, Drago JZ, Liu D, et al. EGFR-directed antibodies promote HER2 ADC internalization and efficacy. Cell Rep Med. 2024;5:101792.","journal-title":"Cell Rep Med"},{"key":"3931_CR36","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1186\/s13046-024-03143-3","volume":"43","author":"J Lee","year":"2024","unstructured":"Lee J, Kida K, Koh J, Liu H, Manyam GC, Gi YJ, et al. The DNA repair pathway as a therapeutic target to synergize with trastuzumab deruxtecan in HER2-targeted antibody\u2013drug conjugate\u2013resistant HER2-overexpressing breast cancer. J Exp Clin Cancer Res. 2024;43:236.","journal-title":"J Exp Clin Cancer Res"},{"key":"3931_CR37","doi-asserted-by":"publisher","first-page":"2839","DOI":"10.1158\/0008-5472.CAN-22-3558","volume":"83","author":"X Cheng","year":"2023","unstructured":"Cheng X, Sun Y, Highkin M, Vemalapally N, Jin X, Zhou B, et al. Breast cancer mutations HER2V777L and PIK3CAH1047R activate the p21\u2013CDK4\/6\u2013cyclin D1 axis to drive tumorigenesis and drug resistance. Cancer Res. 2023;83:2839\u201357.","journal-title":"Cancer Res"},{"key":"3931_CR38","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1038\/s43018-025-00969-4","volume":"6","author":"D Hu","year":"2025","unstructured":"Hu D, Lyu X, Li Z, Ekambaram P, Dongre A, Freeman T, et al. p95HER2, a truncated form of the HER2 oncoprotein, drives an immunosuppressive program in HER2+ breast cancer that limits trastuzumab deruxtecan efficacy. Nat Cancer. 2025;6:1202\u201322.","journal-title":"Nat Cancer"},{"key":"3931_CR39","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/S2213-2600(17)30387-9","volume":"5","author":"RJ Allen","year":"2017","unstructured":"Allen RJ, Porte J, Braybrooke R, Flores C, Fingerlin TE, Oldham JM, et al. Genetic variants associated with susceptibility to idiopathic pulmonary fibrosis in people of European ancestry: a genome-wide association study. Lancet Respiratory Med. 2017;5:869\u201380.","journal-title":"Lancet Respiratory Med"},{"key":"3931_CR40","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac544.2962","volume":"43","author":"K Kokot","year":"2022","unstructured":"Kokot K, Kneuer J, John D, Rebs S, Mueller M, Haas J, et al. Decrease of RNA editing in the failing heart leads to induction of circRNAs. Eur Heart J. 2022;43:ehac544.2962.","journal-title":"Eur Heart J"},{"key":"3931_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-015-1591-4","volume":"15","author":"C Bentin Toaldo","year":"2015","unstructured":"Bentin Toaldo C, Alexi X, Beelen K, Kok M, Hauptmann M, Jansen M, et al. Protein Kinase A-induced tamoxifen resistance is mediated by anchoring protein AKAP13. BMC Cancer. 2015;15:588.","journal-title":"BMC Cancer"},{"key":"3931_CR42","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1093\/intimm\/dxab002","volume":"33","author":"Y Kitai","year":"2021","unstructured":"Kitai Y, Ishiura M, Saitoh K, Matsumoto N, Owashi K, Yamada S, et al. CD47 promotes T-cell lymphoma metastasis by up-regulating AKAP13-mediated RhoA activation. Int Immunol. 2021;33:273\u201380.","journal-title":"Int Immunol"},{"key":"3931_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.754353","volume":"11","author":"Y Liu","year":"2021","unstructured":"Liu Y, Zhao S, Wang J, Zhu Z, Luo L, Xiang Q, et al. MiR-629-5p promotes prostate cancer development and metastasis by targeting AKAP13. Front Oncol. 2021;11:754353.","journal-title":"Front Oncol"},{"key":"3931_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiomed.2025.109809","volume":"188","author":"A Hermawan","year":"2025","unstructured":"Hermawan A, Pamungkas Putri DD, Fatimah N, Rhamandana Putra IM, Lestari IA. \u03b1-chaconine increases the sensitivity of HER2+ breast cancer cells to trastuzumab by targeting acetylcholinesterase. Comput Biol Med. 2025;188:109809.","journal-title":"Comput Biol Med"},{"key":"3931_CR45","first-page":"688","volume":"10","author":"H Li","year":"2020","unstructured":"Li H, Yuan W, Bin S, Wu G, Li P, Liu M, et al. Overcome trastuzumab resistance of breast cancer using anti-HER2 chimeric antigen receptor T cells and PD1 blockade. Am J Cancer Res. 2020;10:688\u2013703.","journal-title":"Am J Cancer Res"},{"key":"3931_CR46","doi-asserted-by":"publisher","first-page":"e0117818","DOI":"10.1371\/journal.pone.0117818","volume":"10","author":"S von der Heyde","year":"2015","unstructured":"von der Heyde S, Wagner S, Czerny A, Nietert M, Ludewig F, Salinas-Riester G, et al. mRNA profiling reveals determinants of trastuzumab efficiency in HER2-positive breast cancer. PLoS One. 2015;10:e0117818.","journal-title":"PLoS One"},{"key":"3931_CR47","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/s41556-024-01572-y","volume":"27","author":"M Licheva","year":"2025","unstructured":"Licheva M, Pflaum J, Babic R, Mancilla H, Els\u00e4sser J, Boyle E, et al. Phase separation of initiation hubs on cargo is a trigger switch for selective autophagy. Nat Cell Biol. 2025;27:283\u201397.","journal-title":"Nat Cell Biol"},{"key":"3931_CR48","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/s41580-023-00585-z","volume":"24","author":"J Debnath","year":"2023","unstructured":"Debnath J, Gammoh N, Ryan KM. Autophagy and autophagy-related pathways in cancer. Nat Rev Mol Cell Biol. 2023;24:560\u201375.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"3931_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33946-x","volume":"13","author":"M Luo","year":"2022","unstructured":"Luo M, Ye L, Chang R, Ye Y, Zhang Z, Liu C, et al. Multi-omics characterization of autophagy-related molecular features for therapeutic targeting of autophagy. Nat Commun. 2022;13:6345.","journal-title":"Nat Commun"},{"key":"3931_CR50","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adk1731","volume":"16","author":"C Larrue","year":"2024","unstructured":"Larrue C, Mouche S, Angelino P, Sajot M, Birsen R, Kosmider O, et al. Targeting ferritinophagy impairs quiescent cancer stem cells in acute myeloid leukemia in vitro and in vivo models. Sci Transl Med. 2024;16:eadk1731.","journal-title":"Sci Transl Med"},{"key":"3931_CR51","doi-asserted-by":"publisher","unstructured":"DeMichele A, Clark AS, Shea E, Bayne LJ, Sterner CJ, Rohn K et al. Targeting dormant tumor cells to prevent recurrent breast cancer: a randomized phase 2 trial. Nat Med. 2025. https:\/\/doi.org\/10.1038\/s41591-025-03877-3.","DOI":"10.1038\/s41591-025-03877-3"},{"key":"3931_CR52","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adh4094","volume":"9","author":"C Banerjee","year":"2023","unstructured":"Banerjee C, Mehra D, Song D, Mancebo A, Park J-M, Kim D-H, et al. ULK1 forms distinct oligomeric states and nanoscopic structures during autophagy initiation. Sci Adv. 2023;9:eadh4094.","journal-title":"Sci Adv"},{"key":"3931_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41419-019-1805-9","volume":"10","author":"H Lu","year":"2019","unstructured":"Lu H, Xiao J, Ke C, Ni X, Xiu R, Tian Q, et al. TOPK inhibits autophagy by phosphorylating ULK1 and promotes glioma resistance to TMZ. Cell Death Dis. 2019;10:1\u201317.","journal-title":"Cell Death Dis"},{"key":"3931_CR54","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/j.ccell.2022.08.014","volume":"40","author":"A Chryplewicz","year":"2022","unstructured":"Chryplewicz A, Scotton J, Tichet M, Zomer A, Shchors K, Joyce JA, et al. Cancer cell autophagy, reprogrammed macrophages, and remodeled vasculature in glioblastoma triggers tumor immunity. Cancer Cell. 2022;40:1111\u201327.e9.","journal-title":"Cancer Cell"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03931-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03931-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03931-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T22:02:16Z","timestamp":1790114536000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03931-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,6]]},"references-count":54,"journal-issue":{"issue":"39","published-print":{"date-parts":[[2026,10,14]]}},"alternative-id":["3931"],"URL":"https:\/\/doi.org\/10.1038\/s41388-026-03931-5","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,6]]},"assertion":[{"value":"2 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}